Metabolic and cardiac side effects of second-generation antipsychotics: What every clinician should know

Journal of Pharmacy Practice

Volumn 22, Issue 5, 2009, Pages 478-488

  Breden, Ericka L ^a   Liu, Mei T ^b   Dean, Stacey R ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

Atypical antipsychotic; Cardiovascular; Hyperprolactinemia; Metabolic; Monitoring

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; ORAL ANTIDIABETIC AGENT; PALIPERIDONE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

BODY WEIGHT; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DRUG MONITORING; HEART DISEASE; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERPROLACTINEMIA; LIPID BLOOD LEVEL; MENTAL HEALTH CARE; METABOLIC DISORDER; ORTHOSTATIC HYPOTENSION; PROFESSIONAL KNOWLEDGE; PROLACTIN BLOOD LEVEL; QT INTERVAL; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; SIDE EFFECT; SUICIDE;

EID: 70649105426     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190008330200     Document Type: Review

References (79)

1. Top 200 Drugs brand drugs by retail dollars in 2007. Drug Topics March 2008. Available at: http://drugtopics.modernmedicine.com/drugtopics/ Pharmacy+Facts+And+Figures/Top-200-brand-drugs-by-retail-dollars-in-2007/ ArticleStandard/Article/detail/500215. Accessed June 30, 2008.
2. Balf G, Stewart TD, Whitehead R, et al. Metabolic adverse events in patients with mental illness treated with antipsychotics: a primary care perspective. Prim Care Companion J Clin Psychiatry. 2008;10:15-24.
3. Herz MK, Liberman RP, Lieberman JA, et al. American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 1997;154 (suppl 4) :1-63.
4. Argo TR, Crismon ML, Miller AL, et al. The Texas Medication Algorithm Project (TMAP) Procedural Manual: Schizophrenia Algorithm. Texas Department of State Health Services; 2007.
5. McEvoy JP, Scheifer PL, Frances A. The expert consensus guidelines series: treatment of schizophrenia. J Clin Psychiatry. 1999;60 (suppl 11) :1-80.
6. Tandon R. Safety and tolerability: how do newer generation "atypical" antipsychotics compare? Psychiatr Q. 2002;73:297-311.
7. Stahl S. Psychopharmacology of Antipsychotics. London: Martin Dunitz Ltd; 1999:49-79.
8. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry. 2004;161:1334-1349.
9. Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry. 2007;68 (suppl 4) :8-13.
10. Wirshing DA. Schizophrenia and obesity: impact of antipsychotic medications. J Clin Psychiatry. 2004;65 (suppl 18) :13-26.
11. Druss BG. Improving medical care for persons with serious mental illness: challenges and solutions. J Clin Psychiatry. 2007;68 (suppl 4) :40-44.
12. Bermudes RA, Keck PE, McElroy SL, eds. Managing Metabolic Abnormalities in the Psychiatrically Ill: A Clinical Guide for Psychiatrists. Arlington, VA: American Psychiatric Publishing; 2007.
13. Titier K, Girodet PO, Verdoux H, et al. Atypical antipsychotics: from potassium channels to torsades de pointes and sudden death. Drug Safety. 2005;28:35-51.
14. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596-601.
15. Allison DB, Mentore JL, Heo M, et al. Antipsychoticinduced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156:1686-1696.
16. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
17. Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 2003;60:82-91.
18. Perez-Iglesias R, Crespo-Facorro B, Amado JA, et al. A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone. J Clin Psychiatry. 2007;68:1733-1740.
19. Casey DE. Metabolic issues and cardiovascular disease in patients with psychiatric disorders. Am J Med. 2005;118 (suppl 2) :15S-22S.
20. Sernyak MJ. Implementation of monitoring and management guidelines for second-generation antipsychotics. J Clin Psychiatry. 2007;68 (suppl 4) :14-18.
21. Wu RR, Zhao JP, Liu ZN, et al. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology. 2006;186:572-578.
22. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80:19-32.
23. Henderson DC. Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence? CNS Drugs. 2002;16: 77-89.
24. Wilson DR, D'Souza L, Sarkar N, et al. New-onset diabetes and ketoacidosis with atypical antipsychotics. Schizophr Res. 2003;59:1-6.
25. Chiu CC, Chen KP, Liu HC, et al. The early effect of olanzapine and risperidone on insulin secretion in atypical-naïve schizophrenic patients. J Clin Psychopharmacol. 2006;26:504-507.
26. Elias AN, Hofflich H. Abnormalities in glucose metabolism in patients with schizophrenia treated with atypical antipsychotic medications. Am J Med. 2008;121:98-104.
27. Buchholz S, Morrow AF, Coleman PL. Atypical antipsychotic-induced diabetes mellitus: an update on epidemiology and postulated mechanisms. Intern Med J. 2008;38:602-606.
28. Church CO, Stevens DL, Fugate SE. Diabetic ketoacidosis associated with aripiprazole. Diabet Med. 2005;22:1440-1443.
29. Reddymasu S, Bahta E, Levine S, et al. Elevated lipase and diabetic ketoacidosis associated with aripiprazole. J Pancreas. 2006;7:303-305.
30. Gaston RL, George M, Azhahan N. Diabetic control and atypical antipsychotics: a case report. J Med Case Reports. 2008;2:155.
31. van Winkel R, De Hert M, Wampers M, et al. Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2008;69: 472-479.
32. Henderson DC, Doraiswamy PM. Prolactin-related and metabolic adverse effects of atypical antipsychotic agents. J Clin Psychiatry. 2008;69 (suppl 1) :32-44.
33. Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes and sudden death. Am J Psychiatry. 2001;158:1774-1782.
34. Merrill DB, Ahmari SE, Bradford JM, et al. Myocarditis during clozapine treatment. Am J Psychiatry. 2006;163: 204-208.
35. Koller E, Schneider B, Bennett K, et al. Clozapineassociated diabetes. Am J Med. 2001;111:716-723.
36. Koller E, Doraiswamy P. Olanzapine-associated diabetes mellitus. Pharmacotherapy. 2002;22:841-852.
37. Koller E, Cross J, Doraiswamy P, et al. Risperidoneassociated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy. 2003;23:735-744.
38. Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry. 2002;14:59-64.
39. Rettenbacher MA, Ebenbichler C, Hofer A, et al. Early changes of plasma lipids during treatment with atypical antipsychotics. Int Clin Psychopharmacol. 2006;21: 369-372.
40. Casey DE. Dyslipidemia and atypical antipsychotic drugs. J Clin Psychiatry. 2004;65 (suppl 18) :27-35.
41. Meyer JM. Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol. 2001;21:369-374.
42. Smith RC, Segman RH, Golcer-Dubner T, et al. Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia. Pharmacogenomics J. 2008;8:228-236.
43. Yamamoto K, Fukuda M, Nogawa A, et al. Decreased lipoprotein lipase as a risk factor for atypical neuroleptic-induced hypertriglyceridemia. J Clin Psychiatry. 2007;68:802.
44. Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone-and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry. 2002;63:425-433.
45. Wirshing DA, Boyd JA, Meng LR, et al. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry. 2002;63:856-865.
46. US FDA, Psychopharmacological Drugs Advisory Committee. Briefing document for Zeldox capsules (ziprasidone hydrochloride), July 19, 2000 [online]. Available at: http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3619b1a.pdf. Accessed July 24, 2008.
47. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421.
48. Kinon BJ, Gilmore JA, Liu H, et al. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology. 2003;28 (suppl 2) : 55-68.
49. Jung DU, Seo YS, Park JH, et al. The prevalence of hyperprolactinemia after long-term haloperidol use in patients with chronic schizophrenia. J Clin Psychopharmacol. 2005;25:613-615.
50. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanism, clinical features and management. Drugs. 2004;64:2291-2314.
51. Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry. 1996;153:466-476.
52. Bushe C, Shaw M. Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics. J Psychopharmacol. 2007;21:768-773.
53. Davidson M, Emsley R, Kramer M, et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER) : results of a 6-week, randomized, placebo-controlled study. Schizophr Res. 2007;93: 117-130. (Pubitemid 46817944)
54. Marder SR, Kramer M, Ford L, et al. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry. 2007;62:1363-1370.
55. Kapur S, Langlois X, Vinken P, et al. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J Pharmacol Exp Ther. 2002;302:1129-1134.
56. Kapur S, Roy P, Daskalakis J, et al. Increased dopamine D2 receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine. Am J Psychiatry. 2001;158:311-314.
57. Knegtering R, Baselmans P, Castelein S, et al. Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am J Psychiatry. 2005;162:1010-1012.
58. Melkersson KI. Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite. Hum Psychopharmacol. 2006;21: 529-532.
59. Crawford AM, Beasley CM Jr, Tollefson GD. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res. 1997;26:41-54.
60. Meltzer HY, Goode DJ, Schyve PM, et al. Effect of clozapine on serum prolactin levels. Am J Psychiatry. 1979;136:1550-1555.
61. Hamner M. The effects of atypical antipsychotics on serum prolactin levels. Ann Clin Psychiatry. 2002;14: 163-173.
62. Shim J, Shin JG, Kelly DL, et al. Adjunctive treatment with a dopamine partial agonist aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebocontrolled trial. Am J Psychiatry. 2007;164:1404-1410.
63. Perkins DO. Antipsychotic-induced hyperprolactinemia: pathophysiology and clinical consequences. Adv Stud Med. 2004;4:S982-S986.
64. Kishimoto T, Watanabe K, Shimada N, et al. Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia. J Clin Psychiatry. 2008;63:385-391.
65. Meaney AM, Smith S, Howes OD, et al. Effects of longtermprolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry. 2004;184:503-508.
66. Montout C, Casadebaig F, Lagnaoui R, et al. Neuroleptics and mortality in schizophrenia: prospective analysis of death in a French cohort of schizophrenia patients. Schizophr Res. 2000;57:146-156.
67. Abdelmawla N, Mitchell A. Sudden cardiac death and antipsychotics Part 2: Monitoring and Prevention. Adv Psychiatr Treat. 2006;12:100-109. (Pubitemid 43338103)
68. Vieweg WV. New generation antipsychotic drugs and QTc interval prolongation. Prim Care Companion J Clin Psychiatry. 2003;5:205-215.
69. Bednar MM, Harrigan EP, Anziano RJ, et al. The QT interval. Prog Cardiovasc Dis. 2001;43 (5 suppl 1) : 1-45.
70. Nemeroff CB, Lieberman JA, Weiden PJ, et al. From clinical research to clinical practice: a 4-year review of ziprasidone. CNS Spectr. 2005;10:S1-S20.
71. Zareba W, Lin DA. Antipsycohtic drugs and QT interval prolongation. Psychiatr Q. 2003;74:291-306.
72. Heinrich TW, Biblo LA, Schneider J. Torsades de pointes associated with ziprasidone. Psychosomatics. 2006;47:264-268.
73. Manini AF, Raspberry D, Hoffman RS, et al.QT prolongation and torsades de pointes following overdose of ziprasidone and amantadine. J Med Toxicol. 2007;3: 178-181.
74. Zemrak WR, Kenna GA. Assoication of antipsychotic and antidepressant drugs with Q-T interval prolongation. Am J Health-Syst Pharm. 2008;65:1029-1038.
75. Hägg S, Spigset O, Bate A, et al. Myocarditis related to clozapine treatment. J Clin Psychopharmacol. 2001;21: 382-388.
76. La Grenade L, Graham D, Trontell A. Myocarditis and cardiomyopathy associated with clozapine use in the United States. N Engl J Med. 2001;345:224-225.
77. Killian JG, Kerr K, Lawrence C, et al. Myocarditis and cardiomyopathy associated with clozapine. Lancet. 1999;354:1841-1845.
78. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs. 2007;21:911-936.
79. Fuller MA, Sajatovic M. Psychotropic Drug Information Handbook. Hudson, OH: Lexi-Comp Inc; 2005:701-702.